Reckitt Benckiser Group PLC (RB.L)
24 May 2013
|Market Cap (Mil.):||£34,876.41|
|Shares Outstanding (Mil.):||719.10|
- U.S. health regulators rejected an experimental drug to treat opioid addiction made by Titan Pharmaceuticals Inc and asked for additional data showing it works, the company said.
* Titan says extremely surprised and disappointed by ruling
April 22 - Headlines Bumi shares halted amid payments concern () Bribery probe lifts Walmart directors' pay ()
LONDON - A severe U.S. cold and flu season helped Reckitt Benckiser , the maker of Strepsils lozenges and Mucinex decongestant, to beat first-quarter revenue expectations.
* Growth driven by U.S. flu season, Dettol and Lysol sales
LONDON - Reckitt Benckiser reported a strong start to 2013 as the maker of Strepsils lozenges and Mucinex decongestant continued to benefit from a severe United States cold and flu season.
LONDON, April 22 - Reckitt Benckiser reported a strong start to 2013 as the maker of Strepsils lozenges and Mucinex decongestant continued to benefit from a severe United States cold and flu season.
LONDON, April 22 - Reckitt Benckiser Group PLC : * Q1 total net revenue 2,517 million STG * Q1 growth (ex rbp) +6% * Strong underlying growth across health & hygiene boosted by higher incidence
Reckitt Benckiser ascends to Citi's European focus list, replacing Danone, with the bank seeing the consumer health company receiving revenue upgrades and continuing its recent run of outperformance.
LONDON - U.S. regulators approved two generic versions of Reckitt Benckiser's heroin addiction drug and rejected its bid to block rival products on the grounds that stricter packaging rules were needed to protect children.
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Reckitt Benckiser Group PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.